Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Conditions: Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIB Breast CancerInterventions: Drug: Tamoxifen Citrate; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Radiation: Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life AssessmentSponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; NSABP Foundation Inc; Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group; American College of SurgeonsActive, not recruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Hormonal Therapy | Hormones | Research | Women